Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical efficacy of dupilumab treatment in patients with IgG4-related disease
KCT0006819Phase 2Not yet recruiting
- Sponsor
- Sanofi
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of dupilumab in IgG4-related disease (IgG4-RD), sponsored by Sanofi. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on KCT0006819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006819.